Overview of the FL personalized cancer vaccine pipeline. Patient samples are acquired and then sequenced (top left). Somatic variants of various types, including SNVs (blue), deletions (red), insertions (green), and fusions (pink), are predicted. Sequence data are analyzed to determine HLA types and B-cell clonotypes for each patient. Variant and clonal B-cell peptide sequences are inferred from variants and analyzed with respect to their predicted expression, proteasome processing, and ability to bind the patient’s MHC class I complexes. Candidates are then selected for vaccine design, and additional analyses are performed to assess manufacturability. Bioinformatic tools used for each step are indicated in italics. CDR3, complementarity-determining region 3; IEDB, Immune Epitope Database. Adapted, per CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), from Richters et al.³⁷